• 1
    Brucato A, Frassi M, Franceschini F, Cimaz R, Faden D, Pisoni MP, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44: 18325.
  • 2
    Mazel JA, El Sherif N, Buyon JP, Boutjdir M. Electrocardiographic abnormalities in a murine model injected with IgG from mothers of children with congenital heart block. Circulation 1999; 99: 19148.
  • 3
    Brucato A, Cimaz R, Catelli L, Meroni P. Anti-Ro-associated sinus bradycardia in newborns. Circulation 2000; 102: E889.
  • 4
    Cimaz R, Meroni PL, Brucato A, Fesstova V, Panzeri P, Goulene K, et al. Concomitant disappearance of electrocardiographic abnormalities and of acquired maternal autoantibodies during the first year of life in infants who had QT interval prolongation and anti-SSA/Ro positivity without congenital heart block at birth. Arthritis Rheum 2003; 48: 2668.
  • 5
    Costedoat-Chalumeau N, Amoura Z, Lupoglazoff JM, Huong DL, Denjoy I, Vauthier D, et al. Outcome of pregnancies in patients with anti-SSA/Ro antibodies: a study of 165 pregnancies, with special focus on electrocardiographic variations in the children and comparison with a control group. Arthritis Rheum 2004; 50: 318794.
  • 6
    Gerosa M, Cimaz R, Stramba-Badiale M, Goulene K, Meregalli E, Trespidi L, et al. Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases: a multicentre prospective study. Rheumatology (Oxford) 2007; 46: 12859.
  • 7
    Yildirir A, Aksoyek S, Calguneri M, Aytemir K, Kabakci G, Ovunc K, et al. QT dispersion as a predictor of arrhythmic events in patients with ankylosing spondylitis. Rheumatology (Oxford) 2000; 39: 8759.
  • 8
    Pirildar T, Sekuri C, Utuk O, Tezcan UK. QT dispersion in rheumatoid arthritis patients with and without Sjogren's syndrome. Clin Rheumatol 2003; 22: 2258.
  • 9
    Cindas A, Gokce-Kutsal Y, Tokgozoglu L, Karanfil A. QT dispersion and cardiac involvement in patients with rheumatoid arthritis. Scand J Rheumatol 2002; 31: 226.
  • 10
    Cardoso CR, Sales MA, Papi JA, Salles GF. QT-interval parameters are increased in systemic lupus erythematosus patients. Lupus 2005; 14: 84652.
  • 11
    Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72: 23B5B.
  • 12
    Surawicz B. The QT interval and cardiac arrhythmias. Ann Rev Med 1987; 38: 8190.
  • 13
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 12717.
  • 14
    Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum 1992; 35: 63040.
  • 15
    Gladman DD, Urowitz MB, Goldsmith CH, Fortin P, Ginzler E, Gordon C, et al. The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum 1997; 40: 80913.
  • 16
    Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus: results from a single center. I. Causes of death. J Rheumatol 1995; 22: 125964.
  • 17
    Jaeggi E, Laskin C, Hamilton R, Kingdom J, Silverman E. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus: a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55: 277884.
  • 18
    McCuiston CH, Shoch EP. Possible discoid lupus erythematosus in newborn infants. Arch Dermatol 1954; 70: 7825.
  • 19
    Clancy RM, Neufing PJ, Zheng P, O'Mahony M, Nimmerjahn F, Gordon TP, et al. Impaired clearance of apoptotic cardiocytes is linked to anti-SSA/Ro and -SSB/La antibodies in the pathogenesis of congenital heart block. J Clin Invest 2006; 116: 241322.
  • 20
    Schmidt KG, Ulmer HE, Silverman NH, Kleinman CS, Copel JA. Perinatal outcome of fetal complete atrioventricular block: a multicenter experience. J Am Coll Cardiol 1991; 17: 13606.
  • 21
    Nield LE, Silverman ED, Taylor GP, Smallhorn JF, Mullen JB, Silverman NH, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105: 8438.
  • 22
    Buyon JP, Clancy RM. Neonatal lupus: basic research and clinical perspectives. Rheum Dis Clin North Am 2005; 31: 299313.
  • 23
    Xiao G, Hu K, Boutjdir M. Direct inhibition of expressed cardiac L- and T-type calcium channels by IgG from mothers whose children have congenital heart block circulation. Circulation 2001; 103: 1599604.
  • 24
    Lazerrini PE, Capecchi PL, Laghi-Pasini F. Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypothesis. Scand J Immunol 2010; 72: 21322.
  • 25
    Lazzerini PE, Acampa M, Guideri F, Capecchi PL, Campanella V, Morozzi G, et al. Prolongation of the corrected QT interval in adult patients with anti-Ro/SSA–positive connective tissue diseases. Arthritis Rheum 2004; 50: 124852.
  • 26
    Lazzerrini PE, Capecchi PL, Guideri F, Bellisai F, Selvi E, Acampa M, et al. Comparison of frequency of complex ventricular arrhythmias in patients with positive versus negative anti-Ro/SSA and connective tissue disease. Am J Cardiol 2007; 100: 102934.
  • 27
    Gordon PA, Rosenthal E, Khamashta MA, Hughes GR. Absence of conduction defects in the electrocardiograms [correction of echocardiograms] of mothers with children with congenital complete heart block. J Rheumatol 2001; 28: 3669.
  • 28
    Costedoat-Chalumeau N, Amoura Z, Hulot JS, Ghillani P, Lechat P, Funck-Brentano C, et al. Corrected QT interval in anti-SSA–positive adults with connective tissue disease: comment on the article by Lazzerini et al [letter]. Arthritis Rheum 2005; 52: 6767.
  • 29
    Lazzerini PE, Capecchi PL, Acampa M, Selvi E, Guideri F, Bisogno S, et al. Arrhythmogenic effects of anti-Ro/SSA antibodies on the adult heart: more than expected? Autoimmun Rev 2009; 9: 404.
  • 30
    Yavuz B, Atalar E, Karadag O, Tulumen E, Ozer N, Akdogan A, et al. QT dispersion increases in patients with systemic lupus erythematous. Clin Rheumatol 2007; 26: 3769.
  • 31
    Nakamura K, Katayama Y, Kusano KF, Haraoka K, Tani Y, Nagase S, et al. Anti-KCNH2 antibody-induced long QT syndrome: novel acquired form of long QT syndrome. J Am Coll Cardiol 2007; 50: 18089.
  • 32
    Ravens U, Cerbai E. Role of potassium currents in cardiac arrhythmias. Eurospace 2008; 10: 11337.
  • 33
    Festa A, D'Agostino R, Rautahariu P, Mykkanen L, Haffner SM. Relation of systemic blood pressure, left ventricular mass, insulin sensitivity, and coronary artery disease to QT interval duration in nondiabetic and type 2 diabetic subjects. Am J Cardiol 2000; 86: 111722.
  • 34
    Brown DW, Giles WH, Greenlund KJ, Valdez R, Croft JB. Impaired fasting glucose, diabetes mellitus, and cardiovascular disease risk factors are associated with prolonged QTc duration: results from the Third National Health and Nutrition Survey. J Cardiovasc Risk 2001; 8: 22733.
  • 35
    Pala AM, Ricciardelli D, Sanna A, Vinattieri MA. The effect of beta blockers on the QT interval: the possible role of mechanisms other than beta block. Minerva Med 1989; 80: 12837.
  • 36
    Logar D, Kveder T, Rozman B, Dobovisek J. Possible association between anti-Ro and myocarditis or cardiac conduction defects in adults with systemic lupus erythematosus. Ann Rheum Dis 1990; 49: 6279.
  • 37
    Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is “normal”. J Cardiovasc Electrophysiol 2006; 17: 3336.
  • 38
    Johnson JN, Ackerman MJ. QTc: how long is too long? Br J Sports Med 2009; 43: 65762.
  • 39
    Drew BJ, Ackerman MJ, Funk M, Gibler WB, Kligfield P, Menon V, et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. J Am Coll Cardiol 2010; 55: 93447.
  • 40
    Salomonsson S, Dorner T, Theander E, Bremme K, Larsson P, Wahren-Herlenius M. A serologic marker for fetal risk of congenital heart block. Arthritis Rheum 2002; 46: 123341.
  • 41
    Sonesson SE, Salomonsson S, Jacobsson LA, Bremme K, Wahren-Herlenius M. Signs of first-degree heart block occur in one-third of fetuses of pregnant women with anti–SSA/Ro 52-kd antibodies. Arthritis Rheum 2004; 50: 125361.
  • 42
    Curtis LE, Ostbye T, Sendersky V, Hutchison S, Allen LaPointe NM, Al-Khatib SM, et al. Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients. Am J Med 2003; 114: 13542.